NHS England Backs Biosimilar-To-Biosimilar Switching As It Counts Adalimumab Savings

 
• By Aidan Fry

Switching between biosimilars does not appear to raise safety concerns, according to NHS England, which is anticipating more than £300m in annual savings from biosimilar competition on adalimumab.

Arrows
Multiple switches between biosimilars do not raise safety concerns. NHS England has stated in a briefing document on adalimumab • Source: Shutterstock

More from Biosimilars

More from Products